General Announcement::Approval to initiate FDA phase 2 study

Issuer & Securities

Issuer/ Manager
TFS CORPORATION LTD.
Securities
TFS CORP US$150M11%N180715 - USQ89752AA93 - 4XAB

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
24-Mar-2014 08:58:21
Status
New
Announcement Sub Title
Approval to initiate FDA phase 2 study
Announcement Reference
SG140324OTHR1EBO
Submitted By (Co./ Ind. Name)
Chris Huish
Designation
Compliance Manager
Effective Date and Time of the event
24/03/2014 09:00:00
Description (Please provide a detailed description of the event in the box below)
TFS Corporation Limited ("TFS", ASX: TFC) today announced that its pharmaceutical partner ViroXis has
received Institutional Review Board ("IRB") approval to initiate Federal Drug Administration ("FDA")
phase 2 study for the treatment of molluscum contagiosum ("MCV") using TFS's East Indian sandalwood
oil ("EISO"). IRB approval is a prerequisite to initiate clinical studies in the United States for prescription
drugs.

Attachments

ASX_FDA_phase_2_initiation_240314_FINAL.pdf
Total size =287K